Total Funding
18
53
Total FundingPost-IPO Equity raised
Growth Score
-20 pts
Heat Score
-39 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
79106
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders
Acquired by 
Aurinia Pharmaceuticals
Marc Belsky: Chief Financial OfficerPast Role: Five Prime Therapeutics, Senior Vice President and Chief Financial Officer- Jack Taunton: Co-Founder
About the Company
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies
between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential.
